| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802411201018 | 241120101 | CETROTIDE PS.INJ.SOL 0,25MG/VIAL BTx1VIAL+1PF.SYRx1ML SOLVENT SOLVENT | 22.46 | 23.56 | 32.47 |
| 05/2018 | 2802411201025 | 241120102 | CETROTIDE PS.INJ.SOL 0,25MG/VIAL BTx7VIALS+7PF.SYR x 1ML SOLVENT 1ML SOLVENT | 145.88 | 153.03 | 184.92 |
For the inhibition of premature LH surges in women undergoing controlled ovarian stimulation
Cetrorelix binds to the gonadotropin releasing hormone receptor and acts as a potent inhibitor of gonadotropin secretion. It competes with natural GnRH for binding to membrane receptors on pituitary cells and thus controls the release of LH and FSH in a dose-dependent manner.
Rapidly absorbed following subcutaneous injection. The mean absolute bioavailability following subcutaneous administration to healthy female subjects is 85%.
~62.8 hours
Following subcutaneous administration of 10 mg cetrorelix to males and females, only unchanged cetrorelix was detected in urine.
* 1.16 L/kg
* 1.28 ml/min·kg [adult healthy female with 3 mg single SC administration]